AlzeCure Pharma Shares Surge 301% on Eli Lilly Deal

Shares of AlzeCure Pharma surged 301% following a deal with pharmaceutical giant Eli Lilly. The agreement involves the licensing of AlzeCure's drug candidate for Alzheimer's disease. Through this collaboration, the company has secured significant financial support and access to the global market. Under the deal, Eli Lilly has acquired global rights to ACD679, AlzeCure's drug candidate for Alzheimer's treatment. The agreement provides AlzeCure with an upfront payment of $10 million and potential milestone payments of up to $500 million upon achieving certain development and commercial milestones. AlzeCure's CEO stated that the deal provides a major boost to the company's R&D efforts and strengthens its mission to develop innovative treatments for Alzheimer's disease. Eli Lilly aims to expand its Alzheimer's portfolio and offer new treatment options to patients through this agreement. Market analysts note that the deal will strengthen AlzeCure's financial position and allow the company to allocate resources to other projects. However, they also emphasize that drug development involves high risks and milestone payments are not guaranteed. This is not investment advice.